 CAMBRIDGE, Mass.--BUSINESS WIRE--Sage Therapeutics Nasdaq: SAGE, a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced it will host the first Sage Science Spotlight webcast focused on an in-depth review of SAGE-718. Sage will provide details on its progress with SAGE-718, the companys lead neuropsychiatry product candidate being explored for the potential treatment of 